What happened in this episode?
Peter Attia speaks with oncologist and author Siddhartha Mukherjee about developments in cancer prevention, early detection, and treatment since Mukherjee’s book The Emperor of All Maladies. Mukherjee argues US cancer mortality is generally declining, while pointing to worrying counter-trends including rising early-onset colorectal cancer and a plateauing decline in breast cancer mortality. On prevention, he emphasises expanding genetic risk knowledge beyond single high-penetrance mutations, and proposes that inflammatory and metabolic states may help determine whether mutation-bearing “sleeper” cells progress to clinically apparent cancer.
On early detection, Mukherjee cautions against deploying multi-cancer blood tests broadly in average-risk populations due to false positives and limited mortality impact, but suggests they may be more useful for high-risk groups. On treatment, he highlights checkpoint inhibitors, CAR-T therapies for certain blood cancers, and new targeted drugs for KRAS-driven cancers, including the prospect of moving such drugs into adjuvant trials after surgery.
The conversation also explores AI’s role in oncology and ageing research. Mukherjee cites an AI analysis of CT scans that reportedly found thymus presence/size correlated with lower disease burden, suggesting immune ageing as a potential intervention target. The pair discuss how GLP-1 drugs and insulin biology might intersect with cancer outcomes, and the limits of current institutional funding for “wellness” and longevity science compared with disease-focused research models.
